Takeda Pharmaceutical (NYSE:TAK) Releases FY 2025 Earnings Guidance

Takeda Pharmaceutical (NYSE:TAK) updated its FY 2025 earnings guidance on Friday. The company provided EPS guidance of 3.160-3.160 for the period. The company issued revenue guidance of $29.4 billion-$29.4 billion, compared to the consensus revenue estimate of $28.5 billion.

Takeda Pharmaceutical Price Performance

Shares of NYSE:TAK opened at $17.18 on Friday. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.37 and a quick ratio of 0.76. Takeda Pharmaceutical has a one year low of $12.99 and a one year high of $17.25. The company’s fifty day moving average price is $15.35 and its 200-day moving average price is $14.79. The firm has a market capitalization of $54.68 billion, a price-to-earnings ratio of 214.79 and a beta of 0.03.

Takeda Pharmaceutical (NYSE:TAK) last posted its quarterly earnings results on Thursday, October 30th. The company reported $0.44 earnings per share for the quarter, hitting the consensus estimate of $0.44. Takeda Pharmaceutical had a net margin of 0.86% and a return on equity of 10.32%. The business had revenue of $7.30 billion during the quarter, compared to the consensus estimate of $8.01 billion. On average, equities research analysts anticipate that Takeda Pharmaceutical will post 1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

TAK has been the subject of a number of analyst reports. Weiss Ratings reissued a “hold (c-)” rating on shares of Takeda Pharmaceutical in a research note on Monday, December 29th. Morgan Stanley started coverage on shares of Takeda Pharmaceutical in a research report on Tuesday, January 13th. They set an “overweight” rating for the company. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold”.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS Group AG grew its stake in shares of Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock worth $86,288,000 after acquiring an additional 1,869,323 shares during the last quarter. Goldman Sachs Group Inc. increased its holdings in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after acquiring an additional 692,404 shares in the last quarter. Arrowstreet Capital Limited Partnership increased its stake in shares of Takeda Pharmaceutical by 132.1% in the third quarter. Arrowstreet Capital Limited Partnership now owns 2,828,778 shares of the company’s stock worth $41,413,000 after purchasing an additional 1,610,088 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in Takeda Pharmaceutical by 407.9% in the 3rd quarter. Qube Research & Technologies Ltd now owns 1,775,845 shares of the company’s stock worth $25,998,000 after purchasing an additional 1,426,184 shares during the period. Finally, Bank of America Corp DE raised its position in shares of Takeda Pharmaceutical by 225.8% during the second quarter. Bank of America Corp DE now owns 1,037,163 shares of the company’s stock valued at $16,035,000 after buying an additional 718,805 shares during the last quarter. Institutional investors own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.